The University of Southampton
University of Southampton Institutional Repository

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
The introduction of nucleot(s)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome of patients with chronic hepatitis B. NAs appear to be safe and induce potent suppression of viral replication. However, they are associated with a low rate of HBsAg seroclearance, the gold standard of successful treatment, and also with a relatively high rate of virological relapse after discontinuation. As a result, long-term treatment is needed. The optimal duration of NA treatment currently remains unclear, nevertheless in some patients NA treatment can be stopped with a relatively low probability of relapse. Whether NAs are able to induce a sustained off-treatment response is an important area for research. This article reviews the relapse rate after cessation of treatment with NAs in chronic hepatitis B patients with the goal of identifying possible predictive factors of relapse.
1108-7471
173-181
Kranidioti, H.
67c560b5-240b-4445-88fd-69bee09e1570
Manolakopoulos, S.
6142cc46-9179-44ed-a562-46e19357a97a
Khakoo, S.I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Kranidioti, H.
67c560b5-240b-4445-88fd-69bee09e1570
Manolakopoulos, S.
6142cc46-9179-44ed-a562-46e19357a97a
Khakoo, S.I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273

Kranidioti, H., Manolakopoulos, S. and Khakoo, S.I. (2015) Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. Annals of Gastroenterology, 28 (2), 173-181. (PMID:25831071)

Record type: Article

Abstract

The introduction of nucleot(s)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome of patients with chronic hepatitis B. NAs appear to be safe and induce potent suppression of viral replication. However, they are associated with a low rate of HBsAg seroclearance, the gold standard of successful treatment, and also with a relatively high rate of virological relapse after discontinuation. As a result, long-term treatment is needed. The optimal duration of NA treatment currently remains unclear, nevertheless in some patients NA treatment can be stopped with a relatively low probability of relapse. Whether NAs are able to induce a sustained off-treatment response is an important area for research. This article reviews the relapse rate after cessation of treatment with NAs in chronic hepatitis B patients with the goal of identifying possible predictive factors of relapse.

Full text not available from this repository.

More information

Accepted/In Press date: 7 November 2014
Published date: 28 June 2015
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 390065
URI: https://eprints.soton.ac.uk/id/eprint/390065
ISSN: 1108-7471
PURE UUID: c6dc5512-f8b7-48e3-a424-3e7c629b2cc1

Catalogue record

Date deposited: 17 Mar 2016 16:21
Last modified: 17 Jul 2017 19:30

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×